| Literature DB >> 23529035 |
Adebayo A Adeniyi1, Peter A Ajibade.
Abstract
In cancer chemotherapy, metal-based complexes have been recognized as the most promising means of inhibiting cancer growth due to the successful application of cis-platin and its derivatives above many of the existing organic anticancer agents. The limitations in their rational design can be traced to the complexity of the mechanism of their operations, lack of proper knowledge of their targets and lack of force fields in docking packages to appropriately define the metal centre of the organometallic complexes. In this paper, some of the promising anticancer complexes of Ru(II) such as the rapta-based complexes formulated as [Ru(η6-p-cymene)L2(pta)] and those with unusual ligands are considered. CatB and kinases which have been experimentally confirmed as possible targets of the complexes are also predicted by the three methods as one of the most targeted receptors while TopII and HDAC7 are predicted by two and one of the methods as best targets. The interesting features of the binding of the complexes show that some of the complexes preferentially target specific macromolecules than the others, which is an indication of their specificity and possibility of their therapeutic combination without severe side effects that may come from competition for the same target. Also, introduction of unusual ligands is found to significantly improve the activities of most of the complexes studied. Strong correlations are observed for the predicted binding sites and the orientation of the complexes within the binding site by the three methods of docking. However there are disparities in the ranking of the complexes by the three method of docking, especially that of Glide.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23529035 PMCID: PMC6270031 DOI: 10.3390/molecules18043760
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
The structures of the metal-based complexes.
| No | Structure/Name | No | Structure/Name | No | Structure/Name | No | Structure/Name |
|---|---|---|---|---|---|---|---|
| 1 | 7 | 12 | 17 | ||||
| 2 | 8 | 13 | 18 | ||||
| 3 | 9 | 14 | 19 | ||||
| 4 | 10 | 15 | 20 | ||||
| 5 | 11 | 16 | 21 | ||||
| 6 |
The docking result of the metal-based complexes against ten receptors using the Glide package in Maestro.
| CatB | DNA gyrase | HDAC7 | HP−NCP | KINASE | rHA | RNR | Top11 | TrxR | TS | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | carbo-rapta-C | −2.14 | −1.68 | −1.41 | −2.67 | −3.45 | −0.97 | −1.51 | −1.70 | −1.00 | |
| 2 | rapta-C-COOH | −1.24 | −1.67 | −1.35 | −0.88 | −2.12 | −1.22 | ||||
| 3 | rapta-C-(OH)2 | −2.50 | −2.14 | −1.38 | −3.02 | −3.26 | −1.49 | −2.52 | −3.12 | −2.84 | −1.91 |
| 4 | rapta-C-NH2(OH) | −2.12 | −1.88 | −1.63 | −1.99 | −3.49 | −1.16 | −3.03 | −2.44 | −1.65 | |
| 5 | oxalo-rapta-C | −2.19 | −2.19 | −2.38 | −2.15 | −4.44 | −2.12 | −0.55 | −2.69 | −3.71 | |
| 6 | raC-NH2 | −2.68 | −2.51 | −1.93 | −3.56 | −5.17 | −2.91 | −1.80 | −3.44 | −2.92 | −2.93 |
| 7 | rapta-B | −3.59 | −2.53 | −2.30 | −2.84 | −3.20 | −2.49 | −2.88 | −3.75 | −2.54 | −1.74 |
| 8 | rapta-B-H2O | −4.04 | −3.18 | −2.16 | −3.41 | −3.10 | −2.40 | −3.52 | −5.68 | −4.10 | |
| 9 | rapta-B-H | −4.01 | −2.63 | −2.83 | −3.03 | −4.06 | −2.96 | −2.81 | −4.67 | −3.16 | −2.56 |
| 11 | rapta-C | −3.36 | −2.34 | −2.62 | −2.46 | −3.31 | −1.88 | −3.32 | −4.18 | −2.49 | −3.09 |
| 12 | rapta-C-H2O | −3.56 | −2.49 | −3.35 | −2.99 | −2.61 | −2.61 | −3.64 | −3.97 | −2.37 | −2.82 |
| 13 | rapta-C-H | −3.68 | −3.08 | −3.44 | −2.79 | −4.34 | −2.66 | −3.82 | −5.09 | −3.00 | −3.06 |
| 14 | rapta-T | −3.25 | −2.65 | −2.71 | −2.39 | −2.01 | −2.53 | −3.91 | −2.56 | −2.74 | |
| 15 | rapta-Ta-CH3 | −3.21 | −2.19 | −2.44 | −2.64 | −2.25 | −2.34 | −3.41 | −3.74 | −2.84 | −3.21 |
| 16 | rapta-Ta-NH2 | −3.05 | −2.56 | −3.06 | −2.97 | −3.96 | −2.68 | −4.15 | −4.76 | −2.73 | −3.22 |
| 17 | rapta-Ta-OH | −3.83 | −3.16 | −3.19 | −3.55 | −3.24 | −3.35 | −4.75 | −5.02 | −2.87 | −4.16 |
| 18 | rapta-T-CF3 | −3.81 | −2.21 | −2.58 | −2.33 | −2.13 | −2.31 | −3.99 | −4.19 | −1.91 | −2.73 |
| 19 | rapta-T-CF3(H2O) | −3.92 | −2.35 | −2.43 | −2.65 | −2.47 | −2.08 | −4.21 | −3.95 | −2.56 | −3.36 |
| 20 | rapta-T-H2O | −3.98 | −2.48 | −2.61 | −2.87 | −3.38 | −2.23 | −3.75 | −4.75 | −2.57 | −3.76 |
| 21 | rClCOO-NH3 | −3.18 | −2.20 | −1.92 | −2.95 | −3.79 | −3.82 | −1.96 | −2.76 | −3.79 | −3.19 |
The docking prediction for metal-based complexes using Gold.
| CatB | DNA-Gyrase | HDAC7 | HP-NCP | Kinase | rHA | RNR | Top11 | TrxR | TS | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | carbo-rapta-C | 50.37 | 40.79 | −39.09 | 21.56 | 39 | 36.51 | 51.46 | 41.13 | 34.48 | 42.45 |
| 2 | rapta-C-COOH | 40.53 | 47.59 | 30.82 | 30.46 | 35.37 | 33.26 | 43.02 | 45.21 | 38.67 | 45.48 |
| 3 | rapta-C-(OH)2 | 45.53 | 39.29 | 37.14 | 21.63 | 42.04 | 39.06 | 38.54 | 60.73 | 41.92 | 52.63 |
| 4 | rapta-C-NH2(OH) | 53.29 | 46.78 | 39.97 | 32.2 | 39.68 | 43.75 | 40.18 | 64.48 | 40.31 | 51.22 |
| 5 | oxalo-rapta-C | 40.94 | 42.48 | 18.01 | 25.28 | 42.51 | 46.79 | 46.62 | 49.95 | 40.75 | 40.28 |
| 6 | raC-NH2 | 32.39 | 26.92 | 30.46 | 25.81 | 27.59 | 29.22 | 24.97 | 30.63 | 35.56 | 30.02 |
| 7 | rapta-B | 45.14 | 31.96 | 32.91 | 22.01 | 34.92 | 29.49 | 28.93 | 41.53 | 37.1 | 34.2 |
| 8 | rapta-B-H2O | 45.94 | 32.76 | 32.4 | 26.36 | 40.14 | 31.73 | 29.32 | 42.14 | 32.71 | 31.72 |
| 9 | rapta-B-H | 45.08 | 32.04 | 38.21 | 40.34 | 33.89 | 41.4 | 40.08 | |||
| 10 | rapta-B-NH2 | 47.66 | 37.76 | 40 | 28.61 | 42.27 | 42.57 | 36.13 | 47.9 | 48.6 | 38.03 |
| 11 | rapta-C | 44.84 | 41.05 | 1.63 | 24.02 | 46.02 | 35.18 | 27.07 | 53.56 | 33.47 | 38.49 |
| 12 | rapta-C-H2O | 40.34 | 39.56 | 10.84 | 26.19 | 42.19 | 36.96 | 36.94 | 52.18 | 37.26 | 37.39 |
| 13 | rapta-C-H | 47.22 | 39.11 | 32.49 | 15.25 | 43.03 | 39.26 | 24.33 | 51.92 | 32.93 | 39.36 |
| 14 | rapta-T | 41.09 | 34.83 | 34.43 | 22.33 | 38.57 | 31.1 | 28.8 | 46.48 | 40.48 | 34.66 |
| 15 | rapta-Ta-CH3 | 50.09 | 38.46 | 38.59 | 25.11 | 39.04 | 35.87 | 29.64 | 48.55 | 30.9 | 38.84 |
| 16 | rapta-Ta-NH2 | 50.46 | 44.05 | 34.02 | 30.56 | 46.61 | 39.58 | 41.03 | 53.8 | 35.93 | 38.7 |
| 17 | rapta-Ta-OH | 49.51 | 43.87 | −4.38 | 28.01 | 38.15 | 34.39 | 42 | 49.75 | 36.91 | 40.75 |
| 18 | rapta-T-CF3 | 45.33 | 32.37 | 33.2 | 22.83 | 39.65 | 30.95 | 31.99 | 43.82 | 37.93 | 35.02 |
| 19 | rapta-T-CF3(H2O) | 46.03 | 27.52 | 29.51 | 26.64 | 43.79 | 29.8 | 34.39 | 45.61 | 30.34 | 31.96 |
| 20 | rapta-T-H2O | 45.13 | 33.69 | 26.55 | 26.86 | 44.12 | 29.71 | 37.95 | 46.1 | 28.8 | 34.72 |
| 21 | rClCOO-NH3 | 35.59 | 38.42 | 38.51 | 28.92 | 32.83 | 32.54 | 33.89 | 40.86 | 39.64 | 48.42 |
The docking prediction for metal-based complexes using Autodock.
| CatB | DNA gyrase | HDAC7 | HP-NCP | Kinase | rHA | RNR | Top11 | TrxR | TS | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | carbo-rapta-C | −9.29 | −8.92 | −8.33 | −3.93 | −6.57 | −6.49 | −5.49 | −4.94 | −3.04 | −8.05 |
| 2 | rapta-C-COOH | −8.33 | −6.63 | −7.68 | −3.06 | −5.51 | −5.02 | −4.12 | −2.63 | −5.32 | −6.66 |
| 3 | rapta-C-(OH)2 | −9.96 | −7.9 | −8.1 | −3.46 | −6.65 | −5.58 | −4 | −3.82 | −6.43 | −6.27 |
| 4 | rapta-C-NH2(OH) | −9.42 | −6.79 | −7.37 | −2.95 | −6.16 | −5.25 | −3.73 | −3.1 | −6.22 | −5.79 |
| 5 | oxalo-rapta-C | −9.11 | −8.35 | −7.93 | −3.66 | −6.44 | −5.52 | −5.16 | −3.8 | −7.26 | −7.15 |
| 6 | raC-NH2 | −3.22 | −2.72 | −3.69 | −2.11 | −3.41 | −2.96 | −2.94 | −1.84 | −2.78 | −2.73 |
| 7 | rapta-B | −5.01 | −3.95 | −4.09 | −2.61 | −3.82 | −4.11 | −2.65 | −2.38 | −2.84 | −3.89 |
| 8 | rapta-B-H2O | −7.16 | −6.21 | −6.95 | −2.98 | −6.3 | −4.72 | −3.79 | −3.22 | −5.69 | −5.46 |
| 9 | rapta-B-H | −4.83 | −4.77 | −5.07 | −2.71 | −4.81 | −4.4 | −2.83 | −2.42 | −3.03 | −4.01 |
| 10 | rapta-B-NH2 | −7.09 | −5.65 | −6.76 | −2.76 | −5.76 | −4.23 | −3.31 | −2.54 | −4.24 | −4.68 |
| 11 | rapta-C | −5.73 | −5.36 | −5.2 | −3.08 | −4.71 | −4.34 | −3.46 | −3.18 | −2.18 | −4.65 |
| 12 | rapta-C-H2O | −8.15 | −6.58 | −6.63 | −3.61 | −6.21 | −5.11 | −3.89 | −2.78 | −5.87 | −5.17 |
| 13 | rapta-C-H | −5.44 | −5.14 | −5.1 | −2.83 | −4.69 | −4.24 | −2.99 | −2.65 | −3.46 | −4.32 |
| 14 | rapta-T | −7.1 | −6.15 | −6.23 | −2.79 | −5.32 | −4.62 | −3.74 | −3.23 | −4.67 | −5.31 |
| 15 | rapta-Ta-CH3 | −5.42 | −4.94 | −4.49 | −3.04 | −4.18 | −4.48 | −3.68 | −2.86 | −2.64 | −4.13 |
| 16 | rapta-Ta-NH2 | −5.02 | −4.76 | −4.37 | −2.96 | −4 | −4.21 | −3.11 | −2.7 | −2.5 | −3.77 |
| 17 | rapta-Ta-OH | −7.15 | −7.03 | −7.51 | −5.14 | −6.48 | −5.83 | −5.32 | −3.98 | −4.58 | −5.99 |
| 18 | rapta-T-CF3 | −5.02 | −4.59 | −4.98 | −1.86 | −4.33 | −3.89 | −2.8 | −2.04 | −1.77 | −3.91 |
| 19 | rapta-T-CF3(H2O) | −6.57 | −5.86 | −5.91 | −2.31 | −5.87 | −4.34 | −3.07 | −2.53 | −4.41 | −4.76 |
| 20 | rapta-T-H2O | −7.27 | −6.26 | −6.61 | −2.9 | −6.32 | −5.04 | −3.62 | −3.23 | −4.89 | −5.52 |
| 21 | rClCOO-NH3 | −5.74 | −4.88 | −5.57 | −2.78 | −5.32 | −4.81 | −3.37 | −3.09 | −4.25 | −3.85 |
The interaction of the binding site residues with first two rank best inhibitors complexes from the three docking methods defining the Complex-receptor existing Hydrogen Bond (HB) and Metal-Receptor (MR) possible interactions with residues within the range of 4.5Å.
| No | Method | Receptor Interactions |
|---|---|---|
| 1 | Autodock | CatBb{[HB: 1.92 Å (O@COO)-(H@imHIS 111E)], MR:4.07Å (arTRP 221E)}; |
| Gyrasea{[HB:1.74Å (O@COO)-(H@NHVAL 120A)]; [MR:4.35Å (NH2ASN 46A)}; | ||
| HDAC7a{[MR:3.52Å (COOH ASP 626A)]}; | ||
| Kinaseb{[HB:1.36 (O@COO)- (H@imHIS 584A)]}; | ||
| rHAa{[MR:4.05Å (NH2 ASN 109A)], [MR:4.21Å (COOH GLU 425A)]}; | ||
| RNRa {[HB:1.99Å (O@COO)- (H@NHTHR 209A)], [HB:2.55Å (N@PTA)- (H@COOHGLU 441A],} | ||
| TSa {[no HB and MR]} | ||
| Gold | CatBb{[MR: 4.32Å (arTRP 221E)]}; | |
| 3 | Autodock | CatBa{[HB:1.59Å (OH1)-(O@COOGLU 122E)], [HB:1.52Å (OH2)-(O@COOH GLU 122E)], [HB:2.52Å (HO2)-(H@NH2GLN 23D)], [MR:3.88Å (CH2GLY 121E)}; |
| Gold | Gyrasea{[MR:4.48Å (COO GLU 50A)], } | |
| Top11b { [HB:2.11Å (O@OH)- (H@NH SER 128A)], [MR:3.97Å (CHSER 127A)], [MR:4.23Å (CO ASN 71A)]} | ||
| TrxRb{ [HB:1.73Å (O@OH)-(H@NH2 ARG 166A)], [MR:3.67Å (NH2ARG 166A)]} | ||
| TSa {[HB:1.11Å (O@OH1)-(H@NH2ARG 218A], [HB:2.30Å (O@OH1)-(H@OH SER 219A], | ||
| 4 | Autodock | CatBa{[HB: 1.44 Å (NH2)-(O@COOH GLU 122E)], MR:3.23Å (CH2 GLY 29D)}; |
| Gyraseb{HB: 1.87 Å (OH)-(H@NH2 ASN 46A)], [MR:2.07Å (CH2ASN 46A)], [MR:4.17Å (CH3ILE 78A)]} | ||
| HDAC7a{[MR:1.87Å (arPHE 679A)], [MR:3.73Å (im HIS 709A) ] } | ||
| TSb {[HB:2.57Å (N@PTA)-(H@OH SER 219A], [MR:2.90Å (SH CYS 198A)], [MR:3.48Å (CH3LEU 195A)]} | ||
| 5 | Autodock | HP-NCPa{[IT:2.90 (N@PTA)-(O@COOGLU 64G)],[MR:3.73Å (COOGLU 61G)]} |
| Gyraseb{[HB:1.78Å (O@COO)-(H@NHVAL 120A)], [MR:4.41Å (COGLY 117A)], | ||
| Top11a{[HB:2.08Å (O@COO)-(H@OHSER 128A)], [MR:3.18Å (COOGLU 134A)]} | ||
| TrxRa{[HB:1.83Å (O@COO)-(H@NHSER 386A)], [MR:3.96Å (COGLY 38A)]} | ||
| TSb {[HB:1.86Å (O@COO)-(H@SHCYS 198A], [HB:2.22Å (CO)-(H@NH ASP 221A], [MR:4.14Å (CH2GLY 225A)]} | ||
| Gold | rHAa {[HB:1.68Å (O@COO)-(H@NH2ASN 111A], [HB:2.08Å (O@COO)-(H@NH ASN 111A], | |
| RNRb {[HB:1.86Å (O@COO1)- (H@NH GLU 623A)], [HB:1.98Å (O@COO1)- (H@NH THR 624A)], HB:2.56Å (O@COO1)- (H@OH THR 624A)], HB:1.98Å (O@COO2)- (H@OH SER 625A)], [IT:2.81Å (N@PTA)- (O@COPRO 621A], [MR:3.40Å (HOTHR 209A)]} | ||
| 6 | Glide | HP-NCPa{[MR:2.42Å (NH3 LYS 113H)]} |
| Kinasea{[MR:3.01Å (NH ASP 593A) ]} | ||
| 8 | Glide | CatBa{[HB:1.96Å (H@H2O)-(O@COOGLU 122E)]} |
| Gyrasea{[HB:1.67Å (H@H2O)-(O@COO ASP 49A)]} | ||
| Top11a{[HB:1.83Å (H@H2O)- (O@OHSER 128A)], [HB:2.04Å (H@H2O)- (O@CO ASN 129A)], | ||
| 9 | Glide | CatBb{[MR:3.09Å (CH2 GLY121E)], [MR:4.29Å (COOH GLY122E)]} |
| TrxRb{[MR:3.42Å OH SER 199A]} | ||
| 10 | Gold | rHAb { [MR:1.55Å (CH3@S(CH3) MET 87A)]} |
| TrxRa{ [MR:4.18Å (ar@ph TYR 200A)]} | ||
| 12 | Autodock | |
| Glide | HDAC7b{[HB:1.64Å (H@H2O)-(O@COOASP 626A)]} | |
| 13 | Glide | HDAC7a{[MR:3.21Å (ar PHE 679A)], [MR:4.42Å (CH3 LEV 810A)]} |
| Kinasea{[MR:3.33Å (ar PHE 582A) ], [MR:3.30Å (CH3ILE 462A)]} | ||
| Top11b{[MR:4.10Å (CH2ASN 70A)], [MR:3.78Å (CH3 ILE 104A)]} | ||
| 15 | Gold | HDAC7b{[MR:2.80Å (arPHE 679A)], [MR:3.52Å (im HIS 709A) ] |
| 16 | Gold | HP-NCPb{[HB: 1.69Å(NH2@ar)-(O@COOH GLU 61G)]} |
| Kinasea{[MR:4.24Å (ar TRP 530A) ], [MR:4.34Å (ar PHE 582A) ] } | ||
| 17 | Autodock | HP-NCPa{[HB:2.044Å(OH@ar)-(O@COTHR 101G)]}; |
| rHAb {[HB:1.88Å (OH@ar)-(O@COPRO 113A], [HB:2.02Å (HO@ar)-(H@NH ARG 145A], | ||
| RNRb {[HB:1.89Å (HO@ar)-(H@NH SER 625A]} | ||
| Top11b {[no HB and MR]} | ||
| Glide | Gyraseb{[MR:3.26Å (CH2 ILE 78A)], [MR:3.99Å (CH2 ASN 46A)]} | |
| Top11b{[HB:1.69Å (OH@ar)- (O@COASP 73A)], [MR:4.33Å (COO GLU 134A)]} | ||
| rHAb {[HB:1.77Å (OH@ar)-(O@CO PRO 110A]} | ||
| RNRa{[HB:1.80Å (OH@ar)- (O@OHSER 625A)], [HB:1.86Å (OH@ar)- (H@NHSER 625A)], [MR:4.08Å (H@OH THR 209A)]} | ||
| TSa{[HB:2.63Å (OH@ar)- (H@NH3ARG 23A)], [MR:4.39Å (NH2 ASP 221A)], | ||
| 19 | Glide | RNRb{[HB andMR]} |
| 20 | Gold | Kinasea{[MR:2.83Å (ar PHE 582A) ], [MR:3.46Å (CH3VAL 470A)] } |
| 21 | Autodock | TrxRb {[HB:1.70Å (H@NH3)-(O1@COOGLU 341A], [HB:2.32Å (H@NH3)-(O2@COOGLU 341A)], |
| Glide | rHAa {[HB:1.74Å (O@COO1)-(H@NH2ARG 144A], [HB:2.03Å (O@COO2)-(H@NH2ARG 145A], | |
| TrxRa {[HB:2.62Å (H@NH3)-(O@CO VAL 291A], [HB:1.85Å (O@COO)-(H@NH ALA 198A], |
The type of the interaction: MR(Metal-Receptor define for any receptor residue within the range of 4.50Å), HB(Hydrogen Bond Interaction) and IT (interaction predicted to be also HB). The signs im (imidazole group), ar (arene group which in some residues like TRP is part of benzopyrole), @ (part of). The superscript “a” and “b” on each receptors indicate the ranking of the ligand as first and second respectively, while superscript “1” and “2” indicates first and second respectively of the same functional group that exist on a residue, {} separate different receptor, [] separate different interaction in the same receptor while () define the atom with its residue that is involved in the interaction.
Figure 1The binding site interaction of complexes 1, 3, 4 and 20 with CatB, TopII, gyrase and kinase, respectively, using Autodock (cyan), Gold (magenta) and Glide (yellow) docking predictions. The colouring of the CatB surface as Figure 1a is from the hydrophilic (red) to hydrophobic (blue) and the HB is represented with green cylinders in Figure 1b–d.
The correlation of the docking results using the Autodock, Gold and Glide packages.
| Autodock | Autodock | Gold | |
|---|---|---|---|
| CatB | 0.27 | −0.50 | 0.10 |
| DNA-Gyrase | 0.54 | −0.32 | −0.33 |
| HDAC7 | −0.13 | −0.33 | −0.38 |
| HP-NCP | 0.24 | −0.17 | −0.18 |
| KINASE | 0.32 | −0.17 | −0.26 |
| rHA | 0.45 | −0.37 | −0.20 |
| RNR | 0.76 | −0.32 | −0.36 |
| topoII | 0.41 | −0.06 | −0.11 |
| TrxR | 0.32 | 0.13 | 0.07 |
| TS | 0.42 | −0.28 | −0.46 |
The statistical results of the QSAR analysis called COMSIA of the Glide docked result.
| Factors | gauss_s | gauss_e | gauss_h | gauss_a | gauss_d | S.D | R^2 | R^2-CV | R^2-Scramble | Stability | F | P | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CatB | 1 | 0.53 | 0.15 | 0.22 | 0.06 | 0.05 | 0.33 | 0.85 | 0.41 | 0.39 | 0.66 | 138.8 | 1.83 |
| DNA gyrase | 1 | 0.52 | 0.17 | 0.19 | 0.08 | 0.04 | 0.53 | 0.53 | 0.19 | 0.39 | 0.86 | 27.2 | 2.41 |
| HDAC7 | 1 | 0.5 | 0.14 | 0.19 | 0.07 | 0.1 | 0.42 | 0.65 | 0.04 | 0.45 | 0.58 | 41.3 | 1.82 |
| HP-NCP | 1 | 0.59 | 0.14 | 0.19 | 0.04 | 0.03 | 0.42 | 0.71 | 0.35 | 0.38 | 0.77 | 58.5 | 6.88 |
| Kinase | 1 | 0.63 | 0.08 | 0.16 | 0.07 | 0.06 | 0.68 | 0.49 | 0.25 | 0.35 | 0.94 | 21.8 | 1.07 |
| rHA | 1 | 0.53 | 0.16 | 0.22 | 0.04 | 0.05 | 0.41 | 0.72 | 0.02 | 0.55 | 0.48 | 52.9 | 3.68 |
| RNR | 1 | 0.63 | 0.13 | 0.15 | 0.05 | 0.04 | 1 | 0.62 | 0.39 | 0.45 | 0.93 | 38.7 | 2.00 |
| TopoII | 1 | 0.43 | 0.18 | 0.18 | 0.07 | 0.14 | 0.45 | 0.65 | 0.27 | 0.45 | 0.72 | 38.4 | 3.78 |
| TrxR | 1 | 0.48 | 0.15 | 0.23 | 0.08 | 0.06 | 0.32 | 0.8 | 0.03 | 0.55 | 0.31 | 92.6 | 1.57 |
| TS | 1 | 0.6 | 0.16 | 0.15 | 0.05 | 0.03 | 0.7 | 0.49 | 0.27 | 0.36 | 0.94 | 23.4 | 6.35 |